Meeting
2017 ASCO Annual Meeting
Racial composition in trials supporting the U.S. approval of anti-cancer new molecular entities (NMEs): 2011- 2016.
Authors
Lola A. Fashoyin-Aje
U.S. Food and Drug Administration, Silver Spring, MD
Lola A. Fashoyin-Aje , Laura L. Fernandes , Steven Lemery , Patricia Keegan , Rajeshwari Sridhara , Jonca C. Bull , Richard Pazdur
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Health Services Research, Clinical Informatics, and Quality of Care
Track
Quality Care/Health Services Research
Sub Track
Access to Care
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6518)
DOI
10.1200/JCO.2017.35.15_suppl.6518
Abstract #
6518
Poster Bd #
340
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Association between Environmental Quality Index and metastatic pancreatic cancer.
First Author: Muhammet Ozer
Poster
2021 ASCO Annual Meeting
Inhibition of histone lysine demethylases with TACH101, a first-in-class pan-inhibitor of KDM4.
First Author: Chandtip Chandhasin
First Author: Lola A. Fashoyin-Aje
Poster
2014 ASCO Annual Meeting
Efficacy and safety of mechlorethamine (MCH) 0.04% gel in mycosis fungoides (MF) after treatment with topical MCH 0.02%.
First Author: Youn H. Kim